Therapeutic efficacy and safety of transfusion of pathogen-inactivated platelets to pediatric patients

被引：0
|
作者：
Van Haute, L.
Benoit, Y.
Bordon, V.
De Moerloose, B.
Vandecruys, E.
Van Lancker, S.
Van Vooren, M.
Vandekerckhove, B.
机构：
[1] Red Cross Flanders, Ghent, Belgium
[2] Univ Hosp Gent, Ghent, Belgium
来源：
VOX SANGUINIS | 2006年 / 91卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：177 / 177
页数：1
相关论文
共 50 条
  • [1] Therapeutic efficacy and safety of transfusion pathogen-inactivated platelets to pediatric patients
    Van haute, I
    Benoit, Y
    Vandecruys, E
    De Moerloose, B
    Van Lancker, S
    Mattheeuws, K
    Vandekerckhove, B
    TRANSFUSION, 2005, 45 (03) : 106A - 106A
  • [2] Safety and efficacy of pathogen-inactivated platelets transfused in routine use to pediatric patients: An interim report.
    Benoit, Y
    Van Haute, I
    Vandecruys, E
    De Moerloose, B
    Van Lancker, S
    Mattheeus, K
    Vandekerckhove, B
    BLOOD, 2004, 104 (11) : 989A - 990A
  • [3] Cryopreservation of UVC pathogen-inactivated platelets
    Waters, Lauren
    Padula, Matthew P.
    Marks, Denese C.
    Johnson, Lacey
    TRANSFUSION, 2019, 59 (06) : 2093 - 2102
  • [4] Pathogen-inactivated blood products for pediatric patients: blood safety, patient safety, or both?
    Jacquot, Cyril
    Delaney, Meghan
    TRANSFUSION, 2018, 58 (09) : 2095 - 2101
  • [5] Haemovigilance and Safety of Pathogen-Inactivated Platelets: Experience of One Transfusion Center During a Seven Year Period
    Agliastro, R. E.
    De Francisci, G.
    Bonaccorso, R.
    Ferrara, D.
    D'Alia, G.
    Bannera, A. Ferrante
    Spicola, D.
    Giancana, B.
    Bellavia, D.
    TRANSFUSION, 2011, 51 : 127A - 127A
  • [6] Cost implications of implementation of pathogen-inactivated platelets
    McCullough, Jeffrey
    Goldfinger, Dennis
    Gorlin, Jed
    Riley, William J.
    Sandhu, Harpreet
    Stowell, Christopher
    Ward, Dawn
    Clay, Mary
    Pulkrabek, Shelley
    Chrebtow, Vera
    Stassinopoulos, Adonis
    TRANSFUSION, 2015, 55 (10) : 2312 - 2320
  • [7] Report of four years of experience in production and clinical efficacy of pathogen-inactivated platelets
    Agliastro, R. E.
    De Francisci, G.
    Bonaccorso, R.
    Spicola, D.
    D'Alia, G.
    Bellavia, D.
    Ferrara, D.
    Bannera, A. Ferrante
    Giancana, A.
    Giancana, B.
    Mazzola, A.
    Nuara, G.
    TRANSFUSION, 2007, 47 (03) : 128A - 129A
  • [8] Hemostatic efficacy of pathogen-inactivated vs untreated platelets: a randomized controlled trial
    van der Meer, Pieter F.
    Ypma, Paula F.
    van Geloven, Nan
    van Hilten, Joost A.
    van Wordragen-Vlaswinkel, Rinie J.
    Eissen, Okke
    Zwaginga, Jaap J.
    Trus, Michael
    Beckers, Erik A. M.
    te Boekhorst, Peter
    Tinmouth, Alan
    Lin, Yulia
    Hsia, Cyrus
    Lee, David
    Norris, Philip J.
    Goodrich, Raymond P.
    Brand, Anneke
    Hervig, Tor
    Heddle, Nancy M.
    van der Bom, Johanna G.
    Kerkhoffs, Jean-Louis H.
    BLOOD, 2018, 132 (02) : 223 - 231
  • [9] Hemostatic Efficacy of Pathogen-Inactivated Blood Components
    Ramsey, Glenn
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2016, 42 (02): : 172 - 182
  • [10] Clinical efficiency of transfusion of pathogen-inactivated platelet concentrates
    Nakastoev, I. M.
    Grachev, A. E.
    Gemdjian, E. G.
    Tsyba, N. N.
    Juravlev, V. V.
    Krechetova, A. V.
    Kastrikina, I. S.
    Vatagina, E. A.
    Ryzhko, V. V.
    Gorodetsky, V. M.
    TERAPEVTICHESKII ARKHIV, 2013, 85 (08) : 77 - 80
12345